News

One year of treatment with ALZ-801 (valiltramiprosate) was found in a Phase 2 trial to improve cognition and lower the levels of disease biomarkers among people with early Alzheimer’s with one or two copies of the apolipoprotein E4 (APOE4) disease-associated genetic variant. Importantly, the investigational therapy from…

Nearly half of Alzheimer’s disease patients treated with TrueBinding’s investigational therapy TB006 for at least three months showed signs of disease reversal or cognitive improvement, according to data from an open-label extension (OLE) study. The findings expand on data from a completed Phase 2a trial (NCT05074498) that…

An innovation passport, the first step in the U.K.’s Innovative Licensing and Access Pathway (ILAP) — intended to accelerate the development and approval of new therapies that address an unmet medical need — has been awarded to AD04, ADvantage Therapeutics’ investigational immunotherapy for mild Alzheimer’s disease. The designation, granted…

Treatment with the experimental therapy BIIB080 led to long-term reductions in the levels of disease-associated tau protein in the brains of people with early Alzheimer’s disease. That’s according to new data from a Phase 1b trial (NCT03186989) presented by Biogen at the International Conference on Alzheimer’s and Parkinson’s…

Alzamend Neuro has completed the clinical portion of a Phase 2 trial testing AL001, an investigational formulation of lithium that the company is developing to treat Alzheimer’s disease and other disorders. Data from the trial now will be collected and analyzed. Top-line results are expected by this summer,…

Cognitive benefits were reported in nearly half of the Alzheimer’s disease patients given simufilam for one year in a clinical trial, while those with early-stage, mild disease appeared to respond best to the experimental medication. That’s according to top-line data from the open-label Phase 2 study (NCT04388254) in 216…

The U.S. Food and Drug Administration (FDA) has agreed to review a request to convert Leqembi’s (lecanemab) accelerated approval to a traditional approval for treating Alzheimer’s disease. The FDA has granted priority review to the supplemental biologics license application (sBLA) and the agency is expected to make a…

DISCERN, a biomarker test reported to accurately diagnose Alzheimer’s disease at its earliest stages, routinely would be used by 90% of physicians who responded to a recent survey. With a positive test using a small skin sample, physicians were some six times more likely to diagnose Alzheimer’s and nearly three times…

The Phase 1 INTERCEPT-AD trial testing the investigational antibody ACU193 in patients with early Alzheimer’s disease has now completed enrollment, according to its developer, Acumen Pharmaceuticals. Top-line results, including safety and proof-of-concept mechanism data, are expected ahead of schedule in the third quarter of this year. “Today’s…

Dosing has begun in a first group of healthy adults in a Phase 1a clinical trial of OLX-07010, Oligomerix’s lead treatment candidate for Alzheimer’s disease and other neurodegenerative disorders. OLX-07010 is an oral small molecule inhibitor of tau self-association — one of the initial steps leading to tau…